In Brief: Coulter Corp.
This article was originally published in The Gray Sheet
Executive Summary
Coulter Corp.: Anticipates approval "very soon" for its Coulter HIV-1 p24 antigen assay for use in blood donor screening. The Miami-based firm says it has submitted all the data requested by the agency since receiving its "approvable letter" in August 1995 ("The Gray Sheet" Aug. 14, 1995, p. 12), including stability and product labeling information. Ortho Diagnostic Systems has exclusive worldwide rights to market the test for screening indications. The test will be run on Ortho's automated Summit system, which already is used with microplate format screening tests for HIV-1, Hepatitis and other diseases...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.